Eloralintide: What the Trials Actually Showed — and Whether You Can Get It

By Kaden, founder of The RX Index — independent guidance for choosing your GLP-1 path. Next scheduled trial-status check: September 2026

Affiliate disclosure: The RX Index may earn a commission if a reader later chooses a provider through a clearly labeled affiliate link. Eloralintide is investigational. We do not sell it, and we do not link to anyone who claims to.

Eloralintide is an investigational once-weekly weight-management shot from Eli Lilly. It is not FDA-approved, and there is no approved retail product a pharmacy, doctor, or telehealth provider can prescribe. In a 48-week Phase 2 trial, the fixed 9 mg group had 20.1% average weight loss under Lilly's efficacy estimand. The current public access path is a registered clinical trial, if you qualify.1223

That last sentence is where most articles stop. It's also where the useful part starts — because “join a trial” only helps if you know which of the five Phase 3 programs may fit you. One rule changes the answer: four programs exclude recent weight-loss medication, while ENLIGHTEN-6 is built around stable weekly incretin use. We'll get to it.56789

Those are the five Phase 3 ENLIGHTEN records — not the whole eloralintide pipeline. Lilly also has Phase 1 and Phase 2 studies, including combination and metabolism studies. We separate them below so “five trials” does not get mistaken for “five studies total.”24252627282930

This page is for you if you saw the 20% number and want to know what's behind it, whether a current study may fit you, or whether the vials you found online are the real thing.

This page is not for you if you're looking for a place to buy eloralintide. There is no FDA-approved retail eloralintide product. We'll show you what the evidence says about online “research” products, and we'll point you somewhere better.

What is the short answer about eloralintide?

Eloralintide is an investigational once-weekly amylin shot, not an approved GLP-1 medicine. Its 48-week Phase 2 study reported 9.5% to 20.1% average weight loss under the efficacy estimand, and five Phase 3 ENLIGHTEN records were enrolling when checked on August 6, 2026.1256789

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Get my personalized GLP-1 action plan →

What we actually verified

We checked the peer-reviewed Phase 2 study, Lilly's full results deck, every current Phase 3 ENLIGHTEN page, other current eloralintide records, FDA compounding rules, and current FDA labels. That lets us separate what is known, what is only a theory, and what has not been announced.1256789101112141516

We didn't summarize other articles. Here's exactly what we opened and checked on August 6, 2026:

• The full Phase 2 results deck Lilly presented at ObesityWeek 2025 — all 30-plus slides, including the dose-by-dose side-effect tables that almost nobody has reported.2
• The peer-reviewed Phase 2 paper published in The Lancet.1
• Lilly's exact Phase 2 result table so the 21.3 kg (47.0 lb) figure and efficacy-estimand numbers are tied to the sponsor's primary release.33
• All five current Phase 3 ENLIGHTEN records on Lilly's trial site, including enrollment goals, dates, public eligibility rules, placebo use, trial length, and planned visits.56789
• Other current or newly registered eloralintide studies so the five Phase 3 records are not mistaken for the full pipeline.242526272829303132
• FDA's current 503A and 503B bulk-substance rules and lists to check whether bulk eloralintide has a current federal compounding path.101112
• An FDA warning letter sent to a peptide seller in March 2026, to see how the agency treats “research use only” labels when a site is really marketing products for human use.13
• The Phase 1 and preclinical papers to separate human findings from rat findings.34
• Current FDA labeling for approved comparison medicines so approved and investigational treatments stay clearly separated.141516

What we could not confirm: any FDA submission date, any launch date, any approved price, the final approved dose, or an oral eloralintide program. No public source we reviewed gives those answers yet.

What is eloralintide?

Eloralintide, also written LY3841136, is an investigational drug from Eli Lilly that activates the amylin receptor pathway. It is being studied as a shot given once a week for weight management in adults. It is not a GLP-1 medicine, and it is not approved by FDA.1223

Here's the simple version of how it works.

When you eat, your pancreas releases insulin and amylin. Insulin helps handle blood sugar. Amylin is part of the signal that says that's enough, you're full.

Eloralintide is an engineered amylin medicine. It is designed to switch on that fullness pathway long enough to support once-weekly dosing.23

Is eloralintide a GLP-1?

No. This is the single most common mix-up, so it's worth being clear.

• Wegovy (semaglutide) works on the GLP-1 receptor.
• Zepbound (tirzepatide) works on two receptors, GIP and GLP-1.
• Eloralintide works through the amylin receptor pathway. Different hormone, different door.21415

Lilly designed it to be selective. Its Phase 2 presentation says eloralintide is about 12 times more potent at amylin receptors than at calcitonin receptors, which are closely related. The theory is that greater selectivity could help tolerability. That's the theory. Later on we'll show you what the side-effect numbers actually looked like, and it's more complicated than the theory suggests.2

Different does not mean better. A new mechanism is a reason to run trials. It is not, by itself, evidence that a drug works better than what's already on the shelf.

Is it a pill?

No current eloralintide study we found uses a pill. Lilly's active program uses a once-weekly injection under the skin.12356789

This trips people up because there are oral amylin-type medicines being studied — just not eloralintide. If someone tells you they have eloralintide pills, that claim does not match the current Lilly program.

What did the eloralintide trial actually show?

In a 48-week Phase 2 study of 263 adults, average weight loss ranged from 9.5% to 20.1% under the efficacy estimand, depending on the study group, compared with 0.4% for placebo. The 20.1% figure came from one group — people assigned to a fixed 9 mg dose. It is a group average from a mid-stage trial, not a guaranteed personal result.12

Let's go through it properly.

How the study was built

• 263 adults, randomly assigned
• 46 research centers, all in the United States
• Ages 18 to 75
• Obesity, or overweight with at least one weight-related condition
• No type 2 diabetes — that was an exclusion
• Everyone got lifestyle and diet counseling, including the placebo group
• 48 weeks of treatment, then about 10 weeks of follow-up
• Neither the participants nor the investigators knew who got what12

One number worth knowing before you read the rest: 297 people were screened and 263 were randomized. That's 34 screen failures, or 11.4%. Roughly one in nine people who tried to join this Phase 2 study did not make it in. That does not predict the acceptance rate for today's Phase 3 studies, but it shows why a public eligibility checklist is never the final answer.2

Results by dose

Source: Lilly's Phase 2 data presented at ObesityWeek 2025, Lilly's exact result table, and the peer-reviewed Phase 2 study. Figures use the efficacy estimand explained below. These were research groups, not approved doses.1233

In plain terms: the higher-dose groups lost more weight on average. Lilly's own summary describes average reductions of about 17% to 20% in the groups that finished at 9 mg.2

The largest group-level mean reduction Lilly reported was 21.3 kg, or 47 pounds, in the fixed 9 mg efficacy-estimand group. Waist size fell by as much as 16.9 cm — about 6.7 inches. Up to 90% of people in an eloralintide group moved down at least one BMI category, and no eloralintide group showed a participant moving up a category in that analysis.233

How many people hit the big numbers?

Averages hide the spread. Here's the part people actually care about:

About 57% of the fixed 9 mg group reached at least 20% weight loss in the reported analysis. In the group that stepped up 6 → 9 mg, it was 50%. In the slower 3 → 6 → 9 mg group, it was 35%.2

So even in the best-performing group, roughly four in ten people did not reach 20%.

What “efficacy estimand” means, and why it matters

You'll see the phrase “efficacy estimand” attached to that 20.1%. It sounds like statistician noise. It isn't — it changes how you should read the number.

Lilly defined the question this way: what would the result look like if all randomized participants remained on their assigned study treatment for 48 weeks, with possible dose interruptions or dose changes? The analysis included all randomized participants and used data collected before permanent treatment discontinuation.1233

Translation: this is an on-treatment efficacy estimate, not a simple average of only the people who finished and not a real-world forecast. It answers a specific trial question. It does not tell you what an everyday population would average after missed doses, treatment changes, cost problems, or stopping.

That's not a trick. It's a prespecified way to report a trial result, and Lilly disclosed it plainly. It just means you should not turn 20.1% into a personal promise.

Here's the part the headlines skip

We're going to be blunt, because you'll figure it out eventually and we'd rather you hear it from us.

That 20.1% comes from one mid-stage trial with 263 people, funded by the company that makes the drug, with no other medicine to compare it against. Everyone in that study was measured against placebo — not against Zepbound, not against Wegovy. So any comparison you've seen putting eloralintide's number next to theirs is a comparison across separate studies with different people, rules, timelines, and statistics. That is not proof of a winner.12

Now here's why that's not a reason to write it off.

Sponsor funding is how drug development usually works — the sponsor has to generate the evidence needed for regulatory review. It doesn't make the data false. It makes transparent reporting, peer review, and bigger trials more important. And bigger trials are exactly what's happening now: five Phase 3 ENLIGHTEN records with a combined enrollment goal of 5,615 participants.56789

A 20% result in Phase 2 is a legitimate reason to be interested. It is not a reason to act like the question is settled.

How confident should you be in these results?

The Phase 2 results are strong enough to justify large Phase 3 trials but not strong enough to establish long-term safety, a final dose, real-world results, or superiority over any approved medicine. The study had 263 participants, ran for 48 weeks, excluded people with type 2 diabetes, and enrolled a group that was about 78% female and 78% White.12

The limits, laid out

Six claims about eloralintide, checked against the evidence

This is the table we'd want if we were you.

Every row on that table is expanded below with the underlying numbers.

What are eloralintide's side effects?

Nausea and fatigue were the most common reported problems in the Phase 2 trial, affecting 32.7% and 26.9% of pooled eloralintide participants. Side effects varied a lot by study group and by how the dose was raised. Serious adverse events occurred in 5.3% of pooled eloralintide participants and 5.8% of placebo participants, and there were no deaths in the trial.2

The full side-effect table

These are the events reported by at least 5% of pooled eloralintide participants, broken out by group. Almost nobody publishes this. It's one of the most useful tables on this page.

Source: Lilly Phase 2 safety presentation. The study groups were small, so a few people could move a percentage sharply.2

Stomach problems and fatigue were generally mild to moderate. Four participants had severe gastrointestinal events, all constipation. There were no severe cases of nausea, diarrhea, vomiting, or fatigue in the presentation.2

The ladder trade — the most useful number we found

Look at the fixed 9 mg group and the slower 3 → 6 → 9 mg group. Both were assigned to a 9 mg endpoint. The difference was how they got there.

Same destination. Very different ride.2

In this trial, the slower schedule was associated with 3.7 percentage points less average weight loss and much lower vomiting, fatigue, and constipation rates. Vomiting was about one-sixth as common, and fatigue was about half as common.

That trade is the single most important practical fact in this dataset, and here's why it matters far beyond the trial: an online vial doesn't come with a tested ladder. No approved starting dose. No approved schedule. No approved four-week steps. Just an unapproved product and a guess.

The 6 mg oddity nobody mentions

Read the table again and something looks wrong. The fixed 6 mg group had worse rates for several common side effects than the group taking 9 mg:

• Nausea: 64.3% at 6 mg vs. 33.3% at 9 mg
• Vomiting: 25.0% at 6 mg vs. 11.1% at 9 mg
• Diarrhea: 35.7% at 6 mg vs. 11.1% at 9 mg
• Every one of the 28 safety participants in the 6 mg group had at least one treatment-emergent adverse event
• 21.4% stopped treatment because of an adverse event, the highest rate of any group2

That's a small group, so a few people can swing the percentages. But it's a real result from the sponsor's own data, and it makes a point worth sitting with: this table does not support a simple rule that a higher dose always meant more side effects. Which is another argument against guessing at home.

How many people stopped?

• Stopped treatment because of adverse events, all eloralintide groups combined: 10.1%
• Stopped treatment because of adverse events, placebo: 7.7%2

Worth noting for context: 35.8% of the placebo group stopped treatment for any reason — higher than every eloralintide group except the fixed 1 mg group, where 46.4% stopped treatment. People stop long studies for many reasons that have nothing to do with a side effect.2

Serious events, listed honestly

Serious adverse events happened in 11 of 208 pooled eloralintide participants (5.3%) and 3 of 52 placebo participants (5.8%). Those percentages were close, and this trial was too small to treat the slight numerical difference as proof that eloralintide lowers serious-event risk. There were no deaths.2

The serious events listed among eloralintide participants were two acute heart attacks and one each of acute kidney injury, atrial flutter, gallstones, Guillain-Barré syndrome, swollen lymph nodes, multiple sclerosis, a musculoskeletal disorder, small-intestinal obstruction, miscarriage, suicidal thoughts, and thalamic stroke. The slide lists serious events whether or not the drug caused them. It does not say eloralintide caused every event.2

The suicidal-thought event deserves detail, because it's the kind of thing that gets stripped of context online. It was reported in the 1 mg group about three and a half months after the person had already stopped study treatment for an unrelated adverse event. Both the investigator and sponsor judged it unrelated to study treatment.2

The study also tracked several prespecified events of special interest:

The study recorded reductions in pulse rate and blood pressure. It also excluded people with an ongoing or past abnormally slow heart rhythm. That does not prove a danger, but it is a clear reason to watch the larger Phase 3 safety data instead of treating the Phase 2 finding as settled.2

What we still don't know about safety

• Uncommon side effects that a 263-person study could miss
• What happens after several years of treatment
• What happens after treatment stops
• Safety with other weight-management medicines outside a trial
• Safety in pregnancy
• The final warnings, contraindications, and monitoring rules that would appear on an approved label

None of the doses above are instructions. Eloralintide has no approved prescribing information. These were research groups, treated under supervision, with monitoring you don't have at home.

Does eloralintide protect muscle?

No human study has shown that eloralintide protects muscle better than GLP-1 medicines. The direct comparison people cite was done in rats. In Lilly's human body-composition substudy, about 60% to 70% of the mass lost was fat — which Lilly's own slide described as “on par with other obesity treatments.”24

This claim spreads fast online, so let's separate the two pieces of evidence.

In rats: eloralintide was linked to less lean-mass loss than cagrilintide, a different investigational amylin medicine. That's a real published finding. It's also a finding in rats, comparing two investigational molecules.4

In people: Lilly ran a body-composition substudy using DXA scans on 135 people at week 24 and 122 people at week 48. The reported fat-loss index was about 60% to 70% across the eloralintide groups.2

Now read the title Lilly put on that slide: the fat-loss share was “on par with other obesity treatments.”2

That's the manufacturer, in its own conference presentation, describing the body composition as comparable — not superior. When the company with every commercial reason to claim an advantage declines to claim one, that tells you something.

So if you've seen eloralintide described as the “muscle-sparing” one, that description is running ahead of the human evidence, and it's running ahead of what Lilly itself says.

For the fat-versus-lean-mass data across other treatments, see our GLP-1 lean mass research tracker.

Can you get eloralintide right now?

There is no FDA-approved eloralintide product that a U.S. pharmacy, doctor, or telehealth provider can prescribe as ordinary retail treatment. The current public access path is a registered clinical trial, if a study is recruiting near you and the trial team decides you qualify.2356789

Why there's no prescription

An investigational drug is one still being tested. Eloralintide has no approved label, so there is no approved dose, approved use, pharmacy product, or retail prescription for a pharmacist to fill.

What about expanded access or compassionate use?

FDA has an expanded-access pathway for some patients with a serious or immediately life-threatening condition when no comparable or satisfactory treatment exists. It is not a consumer ordering program. A licensed doctor, the drug company, an institutional review board, and FDA all have to agree that the request may proceed.22

We found no public Lilly expanded-access program for eloralintide in the sources reviewed. That makes a registered trial the current public path for someone specifically seeking eloralintide. Expanded access should not be sold as a normal shortcut around trial screening or FDA approval.2223

Why we found no current public bulk-compounding basis

This part surprises people, because compounded semaglutide and tirzepatide were widely available under different facts and rules.

For a traditional section 503A compounder to use a bulk drug substance, FDA says the substance generally must meet an applicable USP or National Formulary monograph, be a component of an FDA-approved drug if no monograph exists, or appear on FDA's 503A bulk-substance list. FDA also has an interim Category 1 policy for certain nominated substances.10

For a section 503B outsourcing facility, the bulk substance must generally appear on FDA's 503B clinical-need list, or the compounded drug must appear on FDA's drug-shortage list at the time of compounding, distribution, and dispensing.11

Here is what we verified on August 6, 2026:

Bottom line: we found no current public federal basis for routine retail compounding from bulk eloralintide under sections 503A or 503B. That is not a legal opinion about every fact-specific pharmacy practice. It is a clear reason not to accept “compounded eloralintide” as proof that a product is lawful, FDA-approved, or equivalent to Lilly's trial medicine.101112

The public facts are clear enough: there is no approved eloralintide prescription product, and no eloralintide entry appeared on the FDA bulk-substance lists we checked.

Could you join a trial?

Maybe. It's a real option and worth exploring. Just go in clear-eyed:

• The eligibility rules posted publicly are a summary, not the full protocol
• The study site decides after screening
• You may receive placebo
• A study can be listed as enrolling while the site nearest you is full or not yet open
• Trials take visits, tests, travel, and time56789

Which eloralintide trial may fit you? Compare your diabetes status, current medication, sleep apnea, knee arthritis, BMI, and travel area with the five Phase 3 ENLIGHTEN records. Use the eloralintide trial match table → This narrows the public study records. It does not decide eligibility or guarantee that a site is accepting people. The study team makes that decision after screening.

Which eloralintide trial may fit you?

Start with the biggest public forks: diabetes status, stable weekly incretin use, sleep apnea, knee osteoarthritis pain, BMI, recent weight-loss treatment, and travel area. Those details can narrow the five Phase 3 ENLIGHTEN records, but only the trial team can apply the full protocol and decide whether you qualify.56789

Use this quick match table, then open the official study record before you contact a site:

After you find a likely match, open the official record to check placebo use, study length, the public pre-screen, and currently listed locations. Do not enter a name, phone number, or email address on this page; the official trial site handles contact and screening.

No clear match? That may mean the public rules are incomplete, no nearby site is open, or more than one study could apply. Review the five official records below and ask the study team instead of changing treatment to force a match.

Which Phase 3 eloralintide trials are enrolling right now?

Lilly's Phase 3 program is called ENLIGHTEN. Five named trial records were listed as enrolling when checked on August 6, 2026, covering adults without diabetes, adults with type 2 diabetes, people with sleep apnea, people with knee osteoarthritis pain, and people with persistent obesity or overweight while using stable weekly incretin treatment. Their combined enrollment goal is 5,615 participants.56789

Status, goals, dates, placebo use, public eligibility rules, trial length, and planned visits verified August 6, 2026, against Lilly's trial pages. Recruitment and locations can change at any time. Always confirm with the study team.56789

Are those the only eloralintide studies?

No. The five records above are the Phase 3 ENLIGHTEN program, not the full eloralintide research pipeline. Other recruiting or newly registered studies are testing eloralintide with macupatide, studying how liver or kidney impairment changes drug exposure, measuring insulin sensitivity and metabolism, comparing two injection solutions, and measuring gastric emptying.24252627282930

Two other eloralintide-and-tirzepatide studies were listed as completed enrollment rather than open entry points: a Phase 2 study in 367 adults with type 2 diabetes and a Phase 1 study in 188 adults without diabetes.3132

Why does the public Phase 3 list skip ENLIGHTEN-5? We found no public ENLIGHTEN-5 record in the ClinicalTrials.gov and Lilly pages reviewed on August 6, 2026. That tells us only that no public record with that name was found. It does not tell us why the number was skipped.

Read this before you change any medication

This is the detail we mentioned at the top, and it's the part that can send someone toward the wrong study.

ENLIGHTEN-1, ENLIGHTEN-2, ENLIGHTEN-3, and ENLIGHTEN-4 publicly exclude weight-loss medication or alternative remedies used within 90 days before screening.5678

ENLIGHTEN-6 sits on the other side of the door — it requires stable weekly incretin treatment at screening. The public page does not tell you every drug, dose, or stability detail that the full protocol may require.9

So:

If you're on Zepbound, Wegovy, or another weekly incretin right now and thinking about quitting just to chase ENLIGHTEN-1 — that's backwards. Stopping starts a 90-day exclusion window for ENLIGHTEN-1, while ENLIGHTEN-6 is the study built around stable incretin treatment. You could move yourself from one possible door into a gap between both.

If you're on nothing and considering treatment now, starting a weight-loss medication could begin a 90-day exclusion window for ENLIGHTEN-1 through ENLIGHTEN-4. That does not mean you should delay care for a trial. It means you should ask the trial site and your clinician before changing a treatment plan around study access.

Never stop, delay, or start a prescribed medication just to try to qualify for a study. Talk to the clinician who treats you and the study team. The public checklist is not the full protocol.

Can you buy eloralintide online?

Websites may advertise vials labeled eloralintide or mark them “research use only.” Those products are not an FDA-approved Lilly medicine, and the label does not prove the vial's identity, amount, purity, sterility, or storage history. FDA has warned peptide sellers that a research-only label does not shield a product when the site's claims show it is really being marketed for human use.13

We're not going to lecture you. You can read the same listings we can. What we can do is show you what a listing does — and does not — prove.

We did not buy or laboratory-test online products. That means we will not pretend we know exactly what is inside them. That's the point: neither does the buyer.

What “research use only” actually means

It can describe a product that is not intended for people. It is not a magic legal shield when the rest of a website markets the product like a human drug.

We don't have to guess about that, because FDA has said so in writing. In a warning letter dated March 31, 2026, FDA said a peptide seller's retatrutide and tirzepatide products were unapproved new drugs even though the website labeled them “Research Use Only” and “not intended for human consumption.” FDA pointed to the site's human-use claims as evidence of the real intended use.13

One detail from that letter is worth your attention. The seller called tirzepatide “GLP-2 peptide.” Tirzepatide is a GIP and GLP-1 receptor agonist. GLP-2 is a different hormone. The name was simply wrong.1314

Think about what that means. A seller confident enough to misname a well-known molecule is a seller you're trusting to get identity, amount, purity, and sterility right — with no normal FDA approval review for you to lean on.

FDA also noted that the same site sold bacteriostatic water beside injectable peptide products, which the agency treated as evidence the products were meant to be mixed and injected into people.13

The whole argument in one line: Lilly's eloralintide trial medicine is not for retail sale. A label on an online vial does not prove it contains the same material used in a clinical trial.

How does eloralintide compare with Zepbound, Wegovy, Foundayo, and other amylin drugs?

Eloralintide works through the amylin pathway. Wegovy and Foundayo use the GLP-1 pathway, while Zepbound acts at GIP and GLP-1 receptors. Zepbound, Wegovy, and Foundayo are FDA-approved prescription medicines; eloralintide is not. No head-to-head trial has compared eloralintide with any of them, so separate trial percentages cannot crown a winner.141516

Why you can't just line up the best percentage from each study and pick a winner: the trials can use different people, starting weights, treatment lengths, dose schedules, lifestyle support, missing-data rules, and estimands. Eloralintide's 48-week study and another medicine's longer trial are not one fair race. They're different races.

A real winner requires a direct comparison designed to answer that question. For eloralintide, none exists.

The other amylin drugs

Eloralintide isn't the only amylin-pathway medicine in development. Cagrilintide, petrelintide, and zenagamtide are separate investigational molecules with different designs and programs.181920

We're not going to rerun that entire comparison here — it's a different question and it has its own page. For the broader pipeline, read our guide to amylin agonists for weight loss.

If you've been waiting on eloralintide and just found out it is not available, the more useful question is which treatment path that exists now fits your state, insurance, preferred format, and budget. Find My GLP-1 Path — get your personalized action plan →

When will eloralintide be available?

No FDA submission date, review date, approval date, or launch date has been announced for eloralintide. Current Phase 3 trial records list study end dates from February 2028 through July 2030, but a trial end date is not an approval date. Any page naming a launch year today is estimating, not reporting a confirmed schedule.56789

Anyone giving you a specific launch year is guessing. Here's what would have to happen first:

A Phase 3 study finishing does not guarantee a filing. A filing does not guarantee approval. FDA reviews clinical benefit and risk, labeling, manufacturing, identity, strength, quality, and purity before a new drug may be sold. Approval would not guarantee immediate insurance coverage or easy supply.21

What would change this answer

We will update this page when one of these things happens:

• Lilly reports a major Phase 3 result
• Lilly announces an FDA submission
• FDA accepts an application and sets a review date
• FDA announces an approval or other regulatory action
• Lilly announces a real launch date and price

Until then, the honest answer is simple: no verified availability date exists.

What will eloralintide cost?

There is no approved retail price for eloralintide because there is no approved retail product. Any amount you see today is either a price for an unapproved online product or a guess about a future launch.2123

Short section, because there's nothing to pad it with.

Here is the full price-status audit as of August 6, 2026:

Status verified August 6, 2026, against FDA's drug-approval information and Lilly's eloralintide status page.2123

Two things worth saying:

A clinical trial is not the same as ordinary free medical care. Before you consent, the study team should explain which study treatment, tests, travel, or other costs the sponsor covers. Participation can still cost time, travel, parking, missed work, and other burdens. Compensation and reimbursement vary by study and site. Ask the coordinator directly.

Gray-market prices are not an eloralintide price. A number on a peptide website tells you what a seller charges for a product of unverified identity. It does not tell you what an approved medicine would cost.

If an approved product eventually exists, we will track list price, cash price, insurance rules, prior authorization, savings programs, and supply. Until then, the honest public answer is: no approved-product price exists.

What should you do now?

For most people interested in eloralintide today, there are two realistic paths: look into a registered clinical trial, or work with a licensed clinician on an FDA-approved treatment that is actually available. Buying an online vial is not a third treatment path.

Find yourself below.

You're on a weekly incretin and you've stalled

ENLIGHTEN-6 may be the most relevant public record to check. It is studying people with persistent obesity or overweight while on stable weekly incretin treatment. That does not mean you automatically qualify — the study site still has to apply the full protocol.9

Do not stop your current medicine to chase a different ENLIGHTEN study. Changing treatment could start a 90-day exclusion window for several trials and may also mean you no longer meet ENLIGHTEN-6's stable-treatment rule.

→ Check which ENLIGHTEN record may fit

You're on no weight-loss medicine and want to explore a trial

That's a reasonable thing to investigate. Four public ENLIGHTEN pages exclude recent weight-loss medication within 90 days of screening, but that does not mean you should delay medical care just to preserve trial eligibility.5678

Contact the study first. Ask about the full eligibility rules, placebo, visit schedule, travel, and what happens if you need treatment while waiting.

→ See which ENLIGHTEN study matches your health history

You don't want to wait for an investigational medicine

Fair. Most people don't.

FDA-approved weight-management treatments already include weekly injections and daily tablets. That does not make one of them automatically right for you. The right path depends on your health history, state, insurance, preferred format, and budget.141516

Does that sound like your situation? Get a personalized GLP-1 action plan →

The tool keeps FDA-approved and compounded treatment paths separate and shows the questions to ask before choosing.

You found a website selling eloralintide

Please read the online-vial section above one more time. Then choose one of the paths that does not ask you to trust an unapproved label, guess at a dose, and inject a product you cannot verify.

Questions real people are asking about eloralintide

The recurring questions are whether eloralintide is a pill or shot, how much people lost, how long screening takes, whether current GLP-1 use affects eligibility, and whether online vials are real. The answers below come from official records; forum questions are used only to show what people are trying to understand.

We looked at the questions people raise in trial forums and search boxes. These are questions, not reviews and not medical evidence.

Was it a pill or an injection? Injection. Lilly's current eloralintide program uses a once-weekly shot under the skin. How much did you lose during the trial? A participant story cannot tell you the drug's true average. In a blinded study, a person may not know whether they received eloralintide or placebo, and one person's result is not a typical-result estimate. How long does it take to hear back after applying? It varies by site. Ask the coordinator when you first contact the study. Can I get in if I'm already on Zepbound or Wegovy? ENLIGHTEN-6 may be relevant because it requires stable weekly incretin treatment. The public page is not enough to decide eligibility. Is the eloralintide sold online the same thing? A website label cannot prove that. There is no FDA-approved retail eloralintide product.

Why there are no customer reviews on this page: eloralintide has no approved retail customers because it is not for sale as an approved medicine. Trial stories may come from blinded research, and online-buyer stories cannot verify what was actually in the vial. We're not going to dress either one up as proof.

How we researched this page

The RX Index reviewed Lilly's full Phase 2 presentation from ObesityWeek 2025, the peer-reviewed Phase 2 study, the Phase 1 and preclinical papers, all five current Phase 3 ENLIGHTEN records, other current or newly registered eloralintide studies, FDA's compounding rules and bulk-substance lists, an FDA peptide-seller warning letter, and current FDA labeling for approved comparison medicines. Forum posts were used only to identify questions — never as evidence about safety, efficacy, legality, or eligibility.

Who wrote it: Kaden, founder of The RX Index. This page has not been reviewed by a clinician, and we're not going to pretend otherwise. Medical and regulatory claims are linked to primary or authoritative sources you can open yourself.

How we handled uncertainty: where we couldn't verify something, we said so. We left the approval date, price, final dose, and launch date open instead of filling them with a guess. We labeled rat data as rat data. We did not turn the efficacy estimand into a guaranteed real-world result.

What we left out on purpose: seller names, links to sellers, listing screenshots, reconstitution steps, and anything that could work like dosing instructions for an unapproved product.

Corrections: if something here is wrong or has gone stale, tell us and we'll fix it with a dated note. We don't silently edit material medical or regulatory facts.

Frequently asked questions

These short answers cover eloralintide's FDA status, trial results, side effects, format, access, compounding status, timing, cost, and comparisons. Each answer points back to the primary sources used in the full sections above.

Is eloralintide FDA-approved?

No. It is an investigational drug in Phase 3 trials. There is no FDA-approved retail eloralintide product.2356789

How much weight did people lose on eloralintide?

In the 48-week Phase 2 study, average loss under the efficacy estimand ranged from 9.5% in the 1 mg group to 20.1% in the fixed 9 mg group, compared with 0.4% for placebo. About 57% of the fixed 9 mg group reached at least 20% weight loss.12

Is eloralintide a GLP-1?

No. Eloralintide works through the amylin receptor pathway. Wegovy works at the GLP-1 receptor, and Zepbound works at GIP and GLP-1 receptors.21415

What are eloralintide's side effects?

Nausea (32.7%) and fatigue (26.9%) were most common across the pooled eloralintide groups, followed by constipation, diarrhea, decreased appetite, vomiting, alopecia, upper respiratory infection, and headache. Rates varied sharply by study group and escalation schedule.2

Is eloralintide a pill?

No oral eloralintide program was found in the Lilly studies reviewed for this page. The current program uses a once-weekly injection.2356789

Is eloralintide better than Zepbound or Wegovy?

Unknown. No head-to-head trial has compared them. Zepbound and Wegovy are FDA-approved and available by prescription; eloralintide is not.1415

Does eloralintide protect muscle?

Not proven in people. The direct comparison was done in rats. Lilly's human body-composition slide described the fat-loss share as on par with other obesity treatments.24

Can you buy eloralintide?

There is no FDA-approved retail eloralintide product. The current public access path is a registered clinical trial, if you qualify. An online label does not prove the product is equivalent to Lilly's trial material.5678913

Can I get eloralintide through compassionate use?

FDA expanded access can sometimes allow use of an investigational drug outside a trial for a serious or immediately life-threatening condition when no satisfactory alternative exists. It requires agreement from a doctor, the company, an institutional review board, and FDA. We found no public Lilly expanded-access program for eloralintide.22

Can eloralintide be compounded?

We found no current public federal basis for routine retail compounding from bulk eloralintide under sections 503A or 503B. There is no approved eloralintide product, and no eloralintide entry appeared on the FDA 503A or 503B bulk-substance lists checked August 6, 2026.101112

How do I join an eloralintide trial?

Use the trial match table above to identify a potentially relevant Phase 3 ENLIGHTEN record, then complete Lilly's official pre-screen or contact the listed study site. The separate table above lists other current Phase 1 and Phase 2 studies. Recruiting status changes, and each site makes the final eligibility decision.5678924252627282930

Will I definitely get eloralintide if I join a trial?

No. The current ENLIGHTEN pages say placebo is possible. You may receive placebo, and the study may be blinded.56789

Can I join if I already take Zepbound or Wegovy?

ENLIGHTEN-6 may be relevant because it requires stable weekly incretin treatment. The public page does not provide every rule, so the study team must decide.9

When will eloralintide be available?

No verified filing, approval, launch, or retail-availability date has been announced. Current Phase 3 records list end dates from 2028 through 2030, but those dates do not guarantee approval.56789

How much will eloralintide cost?

There is no approved-product price because there is no approved retail product.2123

What is LY3841136?

LY3841136 is Lilly's development code for eloralintide. They are the same investigational molecule.12

Is eloralintide the same as retatrutide?

No. They are different investigational medicines with different mechanisms. Eloralintide works through the amylin pathway; retatrutide acts at GLP-1, GIP, and glucagon receptors.17

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Find My GLP-1 Path →

Get a personalized action plan based on your state, insurance, preferred treatment path, and budget. FDA-approved and compounded options are always shown separately.

Related reading

• Amylin agonists for weight loss — how eloralintide compares with cagrilintide, petrelintide, and zenagamtide
• What is retatrutide?
• GLP-1 clinical trials tracker
• GLP-1 lean mass by drug

Sources

1. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week Phase 2 trial. The Lancet. 2025. NCT06230523.

2. Eli Lilly and Company. Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity: design, efficacy, body composition, and safety. ObesityWeek 2025.

3. Bhattachar SN, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2026.

4. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. 2025.

5. Eli Lilly. ENLIGHTEN-1 — NCT07321886. Accessed August 6, 2026.

6. Eli Lilly. ENLIGHTEN-2 — NCT07282600. Accessed August 6, 2026.

7. Eli Lilly. ENLIGHTEN-3 — NCT07369011. Accessed August 6, 2026.

8. Eli Lilly. ENLIGHTEN-4 — NCT07353931. Accessed August 6, 2026.

9. Eli Lilly. ENLIGHTEN-6 — NCT07392190. Accessed August 6, 2026.

10. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A. Accessed August 6, 2026.

11. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503B. Accessed August 6, 2026.

12. U.S. Food and Drug Administration. FD&C Act provisions that apply to human drug compounding. Accessed August 6, 2026.

13. U.S. Food and Drug Administration. Warning Letter: Gram Peptides, MARCS-CMS 721806. March 31, 2026.

14. U.S. Food and Drug Administration. Zepbound prescribing information. 2026.

15. U.S. Food and Drug Administration. Wegovy prescribing information. 2026.

16. U.S. Food and Drug Administration. Foundayo prescribing information. 2026.

17. Eli Lilly and Company. What to know about retatrutide. Accessed August 6, 2026.

18. Novo Nordisk. Research and development pipeline. Accessed August 6, 2026.

19. Zealand Pharma. Petrelintide development program. Accessed August 6, 2026.

20. Novo Nordisk Science Hub. Zenagamtide (amycretin), a GLP-1 and amylin receptor agonist. Accessed August 6, 2026.

21. U.S. Food and Drug Administration. Development and approval process for drugs. Accessed August 6, 2026.

22. U.S. Food and Drug Administration. Expanded access information for patients. Accessed August 6, 2026.

23. Eli Lilly and Company. What to know about eloralintide. Accessed August 6, 2026.

24. Eli Lilly. Macupatide and eloralintide in adults with obesity or overweight and type 2 diabetes — NCT07215559. Accessed August 6, 2026.

25. Eli Lilly. Macupatide and eloralintide in adults with obesity or overweight and without diabetes — NCT07589608. Accessed August 6, 2026.

26. ClinicalTrials.gov. Eloralintide in participants with liver impairment and normal liver function — NCT07401862. Accessed August 6, 2026.

27. ClinicalTrials.gov. Eloralintide in participants with kidney impairment and normal kidney function — NCT07426380. Accessed August 6, 2026.

28. ClinicalTrials.gov. Effect of eloralintide on insulin sensitivity and metabolism — NCT07665879. Accessed August 6, 2026.

29. ClinicalTrials.gov. Two eloralintide solutions in healthy participants — NCT07701083. Accessed August 6, 2026.

30. ClinicalTrials.gov. Eloralintide and gastric emptying in adults with obesity or overweight — NCT07738614. Accessed August 6, 2026.

31. Eli Lilly. Eloralintide and tirzepatide in adults with obesity or overweight and type 2 diabetes — NCT06603571. Accessed August 6, 2026.

32. Eli Lilly. Eloralintide alone and with tirzepatide in adults with obesity or overweight — NCT06916065. Accessed August 6, 2026.

33. Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study. November 6, 2025.

Medical disclaimer: This page is for information only and is not medical advice. Eloralintide is an investigational drug that is not approved by FDA. Doses described here were used in supervised clinical trials and are not instructions. Never start, stop, delay, or change a prescription medication based on a web page. Talk to a licensed clinician and the study team about your situation.